MABXIENCE RESEARCH SL.
Location
Madrid
Founded
2015-12-23
Website
Risk Signals
16 news mentions monitored
Industry Context
This company is tracked across risk categories, including those related to its sector (e.g., Commercial Physical and Biological Research), including supply chain integrity, ESG practices, labor disputes, and regulatory compliance.
Filter risk signals by topic
Select a theme below to explore the company’s news mentions in specific risk areas.
Recent Articles about MABXIENCE RESEARCH SL.
Live alerts from global media, monitored by Business Radar
2024-10-04 (citeline.com)
Keytruda? Opdivo? Teva And mAbxience Broaden Partnership With PD-1 Biosimilar
Teva is continuing along its well-trodden path of partnered biosimilar assets, striking a further agreement with Spanish develop mAbxience that could be for the development of either pembrolizumab or nivolumab.
Read more
2023-09-21 (contractpharma.com)
Abbott Labs, mAbxience Enter Biosimilars Mfg. Pact |
mAbxience will manufacture the biosimilars at its GMP approved facilities in Spain and Argentina.
Read more